Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

Exclusion Criteria

• •Patients with squamous cell carcinoma, large cell carcinoma, mixed cell lung cancer
• •The patient has other driver genes that can be treated with targeted drugs
• •Subjects who have previously received immunotherapy with a discontinuation time of less than 3 months
• •Received EGFR-TKI treatment within one week prior to the first administration
• •Received non-specific immunomodulatory therapy
• •Clinical manifestations of neurological failure
• •Non malignant neurological disorders
• •Radiotherapy for the chest and whole brain should be completed within 4 weeks before enrollment
• •Tumor surrounded important blood vessels or had obvious necrosis or cavities
• •Tumor has invaded important surrounding organs and blood vessels
• •History of severe bleeding tendency or coagulation dysfunction
• •The risk of developing esophagotracheal fistula or esophageal pleural fistula